Literature DB >> 2199180

[Treatment of primary osteoporosis with calcium and salmon calcitonin].

J D Ringe1.   

Abstract

Fifty-nine consecutive patients (19 men, 40 women, mean age 60.8 [27-80] years) with primary osteoporosis were studied to see if there was any significant gain in bone mass after treatment with salmon calcitonin. All the patients were given 1 g calcium by mouth every morning. Group 1 (n = 20) received no other specific medication while group 2 (n = 19) were given 100 I.U. calcitonin subcutaneously every second evening and group 3 (n = 20) received the same dose every evening. The pain reported by the patients was subdivided into four severity grades, and analgesic consumption was recorded. In group 1 there was a nonsignificant decrease in pain, but in groups 2 and 3 there was a highly significant diminution in pain (P less than 0.005) and in analgesic intake (P less than 0.01). Measurements of bone density carried out by photon absorption at the end of 12 months showed a 5.5% increase in the distal radius in group 2 (P = 0.0001) and a 7.1% increase in group 3 (P = 0.0001), while in group 1 mineral content had decreased by 4.3% (nonsignificant). These results show that a significant gain in bone mass can be achieved by administration of calcitonin, either daily or on alternate days. The incidence of extravertebral fractures and of new or progressive vertebral deformity tended to be lower in groups 2 and 3 than in group 1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2199180     DOI: 10.1055/s-2008-1065138

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  7 in total

Review 1.  Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials.

Authors:  Jennifer A Knopp; Barry M Diner; Maurice Blitz; George P Lyritis; Brian H Rowe
Journal:  Osteoporos Int       Date:  2004-12-22       Impact factor: 4.507

2.  Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials.

Authors:  J M Cardona; E Pastor
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 3.  Calcitonin in the treatment of osteoporosis.

Authors:  C Gennari; A Camporeale
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 4.  Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis.

Authors:  J A Knopp-Sihota; C V Newburn-Cook; J Homik; G G Cummings; D Voaklander
Journal:  Osteoporos Int       Date:  2011-06-10       Impact factor: 4.507

Review 5.  Effects of calcitonin on bone quality and osteoblastic function.

Authors:  S Wallach; J R Farley; D J Baylink; L Brenner-Gati
Journal:  Calcif Tissue Int       Date:  1993-05       Impact factor: 4.333

Review 6.  Calcitonin for prevention and treatment of postmenopausal osteoporosis.

Authors:  J J Body
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

7.  The effect of treatment with calcitonin on vertebral fracture rate in osteoporosis.

Authors:  P Burckhardt; B Burnand
Journal:  Osteoporos Int       Date:  1993-01       Impact factor: 4.507

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.